肝腔静脉汇合区肝细胞癌经皮射频消融治疗结局的预测因素:倾向性评分匹配分析
该研究纳入2017年1月至2022年1月接受射频消融的86例肝腔静脉汇合区肝细胞癌患者,并以1:1倾向性评分匹配非汇合区肝癌为对照,比较两组技术成功率、主要疗效率和预后,发现两组无显著差异,肿瘤至下腔静脉距离是消融失败的独立危险因素,肿瘤直径是局部肿瘤进展的独立危险因素。
要点
- 肝腔静脉汇合区肝癌射频消融的技术成功率和主要疗效率与非汇合区无显著差异。
- 肿瘤至下腔静脉距离是汇合区肝癌射频消融失败的独立危险因素(OR=0.611,p=0.022)。
- 肿瘤直径是预测汇合区肝癌射频消融后局部肿瘤进展的独立危险因素(HR=2.209,p=0.046)。
核心结论
- 肝腔静脉汇合区肝细胞癌可有效接受射频消融治疗;为最大化疗效,术前应评估肿瘤至下腔静脉距离和肿瘤直径。
研究设计与样本
- 回顾性研究,纳入2017年1月至2022年1月86例肝腔静脉汇合区肝细胞癌射频消融患者,以1:1倾向性评分匹配非汇合区肝癌为对照组,比较并发症、主要疗效率、技术成功率和预后。
诊断标准与关键数值
- 倾向性评分匹配后,汇合区组 vs 非汇合区组技术成功率91.7% vs 95.8%(p=0.491),无显著差异。
- 倾向性评分匹配后,汇合区组 vs 非汇合区组主要疗效率95.8% vs 97.2%(p=1.000),无显著差异。
- 倾向性评分匹配后,汇合区组 vs 非汇合区组1年、3年、5年局部肿瘤进展率12.5% vs 9.9%、28.2% vs 27.7%、40.8% vs 43.8%(p=0.959),无显著差异。
- 倾向性评分匹配后,汇合区组 vs 非汇合区组1年、3年、5年无病生存率87.5% vs 87.5%、62.3% vs 54.2%、18.1% vs 22.6%(p=0.437),无显著差异。
- 倾向性评分匹配后,汇合区组 vs 非汇合区组1年、3年、5年总生存率94.3% vs 95.7%、72.7% vs 69.6%、20.9% vs 33.6%(p=0.904),无显著差异。
临床应用与阅片要点
- 术前应评估肿瘤至下腔静脉距离,该距离是汇合区肝癌射频消融失败的独立危险因素(OR=0.611,p=0.022)。
- 术前应评估肿瘤直径,肿瘤直径是预测汇合区肝癌射频消融后局部肿瘤进展的独立危险因素(HR=2.209,p=0.046)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To compare the efficacy and complications of ultrasound-guided percutaneous radiofrequency ablation of hepatocellular carcinoma (HCC) in the hepatocaval confluence with those of HCC in the non-hepatocaval confluence and to explore the risk factors that lead to radiofrequency ablation failure and patient local tumor progression (LTP).
MATERIALS AND METHODS: From January 2017 to January 2022, 86 patients with HCC in the hepatocaval confluence who had radiofrequency ablation were included. A 1:1 propensity-matched group of patients with HCC in the non-hepatocaval confluence with comparable clinical baseline traits, such as tumor diameter and tumor number, served as the control group. The two groups' complications, primary efficacy rate (PER), technical success rate (TSR), and prognosis were estimated.
RESULTS: After PSM, no significant difference of TSR (91.7% vs 95.8%, p = 0.491) and PER (95.8% vs 97.2%, p = 1.000) and 1-, 3-, and 5-year LTP rate (12.5% vs 9.9%, 28.2% vs 27.7%, 40.8% vs 43.8%, p = 0.959) and 1-, 3-, and 5-year DFS rate (87.5% vs 87.5%, 62.3% vs 54.2%, 18.1% vs 22.6%, p = 0.437) and 1-, 3-, and 5-year OS rate (94.3% vs 95.7%, 72.7% vs 69.6%, 20.9% vs 33.6%, p = 0.904) was detected between the two groups. The tumor-to-IVC distance was an independent risk factor for radiofrequency ablation failure in HCC patients in the hepatocaval confluence (OR = 0.611, p = 0.022). Besides, tumor diameter was an independent risk factor for predicting LTP in patients with HCC in the hepatocaval confluence (HR = 2.209, p = 0.046).
CONCLUSION: HCC in the hepatocaval confluence can be effectively treated with radiofrequency ablation. To maximize treatment efficacy, the tumor-to-IVC distance and tumor diameter should be assessed before the operation begins.
引用
- Zhou, Yuan, Yang, et al. Predictive Factors of Treatment Outcomes After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in the Hepatocaval Confluence: A Propensity Score Matching Analysis. Acad Radiol. 2023. PMID: 37173236. doi:10.1016/j.acra.2023.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。